Law360, New York (June 02, 2011, 7:44 PM ET) -- GlaxoSmithKline PLC on Thursday lost a bid for summary judgment in three antitrust cases pending in Pennsylvania that allege the company delayed sales of a generic version of Flonase by filing baseless petitions with the U.S. Food and Drug Administration.
The lawsuits brought by classes of direct and indirect Flonase purchasers and generics maker Roxane Laboratories Inc. claim that GSK stymied the release of the generic of Flonase, fluticasone propionate, by filing multiple “citizen petitions” with the FDA shortly before the company’s exclusive marketing rights for...
GSK Denied Quick Win In Flonase Antitrust Cases
To view the full article, take a free trial now.
